Regulação e direito · 27/10/19971 min de leitura
Prospective Grant of Exclusive License: IL-4 Pseudomonas Exotoxin Fusion Protein Therapeutics
Tradução automática local · Idioma original da fonte
Resumo
This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Sec. 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive world-wide license to practice the invention embodied in USPA SN 06/911,227 (U.S. Patent 4,892,827) entitled, ``Recombinant Pseudomonas Exotoxins: Construction of an Active Immunotoxin with Low Side Effects''; USPA SN 08/225,224 (U.S. Patent 5,635,599) entitled, ``Circularly Permuted Ligands and Circularly Permuted Chimeric Molecules''; USPA SN 08/722,258 entitled, ``Proteins Comprising Circularly Permuted Ligands''; and USPA SN 08/ 616,785 entitled, ``Convection-Enhanced Drug Delivery'', to Neurocrine Biosciences of San Diego, California. The patent rights in these inventions have been assigned to the United States of America. The field of use would be limited to IL-4 pseudomonas exotoxin fusion protein therapeutics.